Q3 EPS Estimate for Tango Therapeutics Boosted by Analyst

Key Points

• B. Riley has raised its Q3 2025 earnings per share estimate for Tango Therapeutics to $0.10, a significant increase from the previous estimate of ($0.33).
• Guggenheim increased its price target for Tango Therapeutics from $8.00 to $10.00 and maintained a "buy" rating for the stock.
• Shares of Tango Therapeutics rose by 5.5%, closing at $6.76, reflecting the positive adjustments from analysts and investors.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - B. Riley boosted their Q3 2025 earnings estimates for shares of Tango Therapeutics in a report released on Monday, August 11th. B. Riley analyst Y. Zhi now expects that the company will earn $0.10 per share for the quarter, up from their prior estimate of ($0.33). The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. B. Riley also issued estimates for Tango Therapeutics' Q4 2025 earnings at ($0.39) EPS and FY2025 earnings at ($1.00) EPS.

Separately, Guggenheim upped their price objective on shares of Tango Therapeutics from $8.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th.

Tango Therapeutics Stock Performance

NASDAQ:TNGX traded down $0.15 during midday trading on Wednesday, reaching $6.77. 1,017,497 shares of the stock traded hands, compared to its average volume of 1,828,687. The company has a fifty day moving average of $5.89 and a 200 day moving average of $3.30. Tango Therapeutics has a 12 month low of $1.03 and a 12 month high of $12.02. The stock has a market capitalization of $753.23 million, a P/E ratio of -5.09 and a beta of 1.64.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.35) EPS for the quarter, meeting analysts' consensus estimates of ($0.35). Tango Therapeutics had a negative net margin of 599.11% and a negative return on equity of 79.72%. The company had revenue of $3.18 million during the quarter, compared to analyst estimates of $6.41 million.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its stake in shares of Tango Therapeutics by 44.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company's stock worth $49,000 after acquiring an additional 2,907 shares in the last quarter. Northeast Financial Consultants Inc bought a new position in shares of Tango Therapeutics in the 2nd quarter worth about $51,000. Soleus Capital Management L.P. bought a new stake in Tango Therapeutics during the 2nd quarter valued at about $3,738,000. Balyasny Asset Management L.P. raised its holdings in Tango Therapeutics by 0.9% in the second quarter. Balyasny Asset Management L.P. now owns 3,247,463 shares of the company's stock worth $16,627,000 after buying an additional 27,892 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Tango Therapeutics in the second quarter worth about $30,235,000. 78.99% of the stock is currently owned by institutional investors.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.